Human	O
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion-associated	B-protein
regulatory	I-protein
protein	I-protein
.	O

The	O
vpr	B-protein
product	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B-protein
protein	I-protein
.	O

The	O
vpr	B-protein
product	I-protein
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	B-DNA
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O
protein	O
synthesis	O
occurs	O
.	O

JOURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
June	NULL
1990	NULL
,	NULL
p.	NULL
3097-3099	NULL
0022-538	NULL
X/90/063097-03	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

6	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
vpr	NULL
Product	NULL
Is	NULL
a	NULL
Virion-Associated	NULL
Regulatory	NULL
Protein	NULL
ERIC	NULL
A.	NULL
COHEN	NULL
,	NULL
*	NULL
GHASSAN	NULL
DEHNI	NULL
,	NULL
JOSEPH	NULL
G.	NULL
SODROSKI	NULL
,	NULL
anp	NULL
WILLIAM	NULL
A.	NULL
HASELTINE	NULL
Division	NULL
of	NULL
Human	NULL
Retrovirology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
44	NULL
Binney	NULL
Street	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
Received	NULL
4	NULL
January	NULL
1990/Accepted	NULL
5	NULL
March	NULL
1990	NULL
The	NULL
vpr	NULL
product	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
acts	NULL
in	NULL
frans	NULL
to	NULL
accelerate	NULL
virus	NULL
replication	NULL
and	NULL
cytopathic	NULL
effect	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Here	NULL
it	NULL
is	NULL
shown	NULL
that	NULL
the	NULL
HIV-1	NULL
viral	NULL
particle	NULL
contains	NULL
multiple	NULL
copies	NULL
of	NULL
the	NULL
vypr	NULL
protein	NULL
.	NULL

The	NULL
vpr	NULL
product	NULL
is	NULL
the	NULL
first	NULL
regulatory	NULL
protein	NULL
of	NULL
HIV-1	NULL
to	NULL
be	NULL
found	NULL
in	NULL
the	NULL
virus	NULL
particle	NULL
.	NULL

This	NULL
observation	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
vpr	NULL
acts	NULL
to	NULL
facilitate	NULL
the	NULL
early	NULL
steps	NULL
of	NULL
infection	NULL
before	NULL
de	NULL
novo	NULL
viral	NULL
protein	NULL
synthesis	NULL
occurs	NULL
.	NULL

The	NULL
gag	NULL
,	NULL
pol	NULL
,	NULL
and	NULL
env	NULL
genes	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
encode	NULL
the	NULL
structural	NULL
and	NULL
replicative	NULL
proteins	NULL
that	NULL
are	NULL
incorporated	NULL
into	NULL
the	NULL
virus	NULL
particle	NULL
.	NULL

HIV-1	NULL
specifies	NULL
at	NULL
least	NULL
six	NULL
additional	NULL
proteins	NULL
which	NULL
regulate	NULL
viral	NULL
replication	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Two	NULL
of	NULL
these	NULL
genes	NULL
,	NULL
tat	NULL
and	NULL
rev	NULL
,	NULL
are	NULL
essential	NULL
for	NULL
virus	NULL
replication	NULL
.	NULL

The	NULL
remaining	NULL
genes	NULL
,	NULL
nef	NULL
,	NULL
vif	NULL
,	NULL
vpu	NULL
,	NULL
and	NULL
vpr	NULL
,	NULL
are	NULL
not	NULL
required	NULL
for	NULL
virus	NULL
replication	NULL
,	NULL
although	NULL
mutations	NULL
in	NULL
these	NULL
genes	NULL
alter	NULL
the	NULL
replication	NULL
properties	NULL
of	NULL
the	NULL
virus	NULL
(	NULL
3	NULL
)	NULL
.	NULL

vpr	NULL
was	NULL
recently	NULL
demonstrated	NULL
to	NULL
accelerate	NULL
the	NULL
replication	NULL
and	NULL
the	NULL
cytopathic	NULL
effect	NULL
of	NULL
HIV-1	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
5	NULL
)	NULL
.	NULL

vpr	NULL
was	NULL
also	NULL
shown	NULL
to	NULL
specify	NULL
a	NULL
15-kilodalton	NULL
(	NULL
kDa	NULL
)	NULL
protein	NULL
that	NULL
acts	NULL
in	NULL
frans	NULL
to	NULL
increase	NULL
expression	NULL
of	NULL
viral	NULL
proteins	NULL
.	NULL

vpr	NULL
also	NULL
stimulates	NULL
expression	NULL
of	NULL
heterologous	NULL
genes	NULL
driven	NULL
by	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
as	NULL
well	NULL
as	NULL
other	NULL
promoters	NULL
(	NULL
2	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
vpr	NULL
protein	NULL
is	NULL
incorporated	NULL
into	NULL
the	NULL
virus	NULL
particle	NULL
,	NULL
CD4*®	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
infectious	NULL
proviruses	NULL
isogenic	NULL
except	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
vpr	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
technique	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
provirus	NULL
that	NULL
expresses	NULL
the	NULL
full-length	NULL
vpr	NULL
protein	NULL
of	NULL
96	NULL
amino	NULL
acids	NULL
is	NULL
designated	NULL
HXBRU	NULL
*	NULL
.	NULL

A	NULL
provirus	NULL
isogenic	NULL
except	NULL
for	NULL
a	NULL
frameshift	NULL
mutation	NULL
in	NULL
vpr	NULL
that	NULL
is	NULL
predicted	NULL
to	NULL
terminate	NULL
the	NULL
product	NULL
at	NULL
amino	NULL
acid	NULL
40	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
(	NULL
HXBRU~	NULL
)	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Eight	NULL
days	NULL
posttransfection	NULL
,	NULL
both	NULL
cultures	NULL
were	NULL
metabol-ically	NULL
labeled	NULL
with	NULL
100	NULL
wCi	NULL
of	NULL
[	NULL
**S	NULL
)	NULL
Jcysteine	NULL
per	NULL
ml	NULL
for	NULL
8	NULL
h	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
by	NULL
centrifuga-tion	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
lysed	NULL
with	NULL
750	NULL
pl	NULL
of	NULL
a	NULL
buffer	NULL
which	NULL
contained	NULL
0.05	NULL
M	NULL
Tris	NULL
hydro-chloride	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
,	NULL
0.15	NULL
M	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
1	NULL
%	NULL
sodium	NULL
deoxycholate	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
.	NULL

The	NULL
medium	NULL
containing	NULL
the	NULL
virus	NULL
particle	NULL
was	NULL
centrifuged	NULL
at	NULL
800	NULL
x	NULL
g	NULL
and	NULL
passed	NULL
through	NULL
a	NULL
0.22-wm-pore-size	NULL
filter	NULL
to	NULL
prevent	NULL
cell	NULL
contamination	NULL
of	NULL
the	NULL
supernatant	NULL
.	NULL

Cell-free	NULL
supernatants	NULL
were	NULL
then	NULL
centrifuged	NULL
for	NULL
1	NULL
h	NULL
at	NULL
16,000	NULL
rpm	NULL
in	NULL
an	NULL
Eppendorf	NULL
microcentrifuge	NULL
.	NULL

Lysates	NULL
were	NULL
prepared	NULL
from	NULL
both	NULL
the	NULL
labeled	NULL
transfected	NULL
cells	NULL
and	NULL
from	NULL
the	NULL
virus	NULL
peliets	NULL
.	NULL

The	NULL
cell	NULL
and	NULL
viral	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
)	NULL
with	NULL
antiserum	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
which	NULL
recognized	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
viral	NULL
structural	NULL
proteins	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
also	NULL
precipitated	NULL
with	NULL
a	NULL
monospecific	NULL
anti-vpr	NULL
serum	NULL
.	NULL

The	NULL
rabbit	NULL
vpr	NULL
antiserum	NULL
used	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
synthetic	NULL
peptide	NULL
correspond	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

3097	NULL
ing	NULL
to	NULL
the	NULL
amino-terminal	NULL
19	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
vpr	NULL
protein	NULL
.	NULL

As	NULL
described	NULL
previously	NULL
(	NULL
2	NULL
)	NULL
,	NULL
this	NULL
antiserum	NULL
recognizes	NULL
a	NULL
15-kDa	NULL
protein	NULL
in	NULL
cells	NULL
producing	NULL
the	NULL
vpr	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
peptide	NULL
used	NULL
to	NULL
raise	NULL
the	NULL
antiserum	NULL
competed	NULL
for	NULL
recognition	NULL
of	NULL
the	NULL
15-kDa	NULL
protein	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
vpr	NULL
product	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
cells	NULL
producing	NULL
the	NULL
HXBRU~	NULL
virus	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
vpr	NULL
peptide	NULL
antiserum	NULL
also	NULL
recognized	NULL
the	NULL
15-kDa	NULL
protein	NULL
in	NULL
the	NULL
lysates	NULL
of	NULL
pelleted	NULL
virus	NULL
prepared	NULL
from	NULL
cells	NULL
producing	NULL
the	NULL
HXBRU*	NULL
virus	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

No	NULL
vpr	NULL
product	NULL
was	NULL
detected	NULL
in	NULL
viruses	NULL
pelleted	NULL
from	NULL
cultures	NULL
producing	NULL
the	NULL
HXBRU~	NULL
virus	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
protein	NULL
of	NULL
approximately	NULL
9	NULL
kDa	NULL
of	NULL
molecular	NULL
mass	NULL
was	NULL
detected	NULL
only	NULL
in	NULL
viruses	NULL
pelleted	NULL
from	NULL
cultures	NULL
producing	NULL
the	NULL
HXBRU*	NULL
and	NULL
HXBRU~	NULL
viruses	NULL
with	NULL
both	NULL
the	NULL
vpr	NULL
peptide	NULL
antiserum	NULL
and	NULL
the	NULL
AIDS	NULL
patient	NULL
serum	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
.	NULL

The	NULL
recognition	NULL
of	NULL
this	NULL
9-kDa	NULL
protein	NULL
was	NULL
not	NULL
competed	NULL
for	NULL
by	NULL
the	NULL
vpr	NULL
peptide	NULL
,	NULL
suggesting	NULL
a	NULL
nonspecific	NULL
reaction	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
vpr	NULL
protein	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
virus	NULL
particle	NULL
.	NULL

The	NULL
association	NULL
appears	NULL
to	NULL
t-O	NULL
--	NULL
Ow	NULL
tat	NULL
(	NULL
)	NULL
tat	NULL
m	NULL
vpu	NULL
rev	NULL
D	NULL
(	NULL
C	NULL
--	NULL
)	NULL
ti	NULL
gag	NULL
vpr	NULL
rev	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
L	NULL
1	NULL
i	NULL
1	NULL
1	NULL
1	NULL
L	NULL
1	NULL
L	NULL
1	NULL
1	NULL
A	NULL
t	NULL
¢	NULL
EcoRI	NULL
_	NULL
Nco	NULL
!	NULL

Kpn	NULL
!	NULL

(	NULL
4193	NULL
)	NULL
-	NULL
(	NULL
S255	NULL
)	NULL
(	NULL
5893	NULL
)	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Genetic	NULL
organization	NULL
of	NULL
HIV-1	NULL
.	NULL

Arrows	NULL
indicate	NULL
the	NULL
initiator	NULL
AUG	NULL
codons	NULL
in	NULL
viral	NULL
genes	NULL
.	NULL

To	NULL
generate	NULL
a	NULL
vpr*	NULL
provirus	NULL
,	NULL
a	NULL
segment	NULL
of	NULL
the	NULL
HXBc2	NULL
provirus	NULL
(	NULL
6	NULL
)	NULL
located	NULL
between	NULL
the	NULL
C	NULL
terminus	NULL
of	NULL
pol	NULL
(	NULL
EcoRI	NULL
at	NULL
nucleotide	NULL
position	NULL
4193	NULL
;	NULL
+1	NULL
is	NULL
the	NULL
site	NULL
of	NULL
initiation	NULL
of	NULL
transcription	NULL
)	NULL
and	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
env	NULL
(	NULL
KpnI	NULL
site	NULL
at	NULL
nucleotide	NULL
5893	NULL
)	NULL
,	NULL
a	NULL
region	NULL
that	NULL
contains	NULL
the	NULL
entire	NULL
vpr	NULL
coding	NULL
sequence	NULL
(	NULL
BA	NULL
)	NULL
,	NULL
was	NULL
replaced	NULL
with	NULL
the	NULL
corresponding	NULL
segment	NULL
derived	NULL
from	NULL
the	NULL
closely	NULL
related	NULL
BRU	NULL
provirus	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
genotype	NULL
of	NULL
the	NULL
resultant	NULL
provirus	NULL
(	NULL
HXBRU*	NULL
)	NULL
is	NULL
5°	NULL
LTRpxse	NULL
»	NULL
£48	NULL
uxBe2	NULL
PO	NULL
xn	NULL
vif	NULL
``	NULL
srv	NULL
YP	NULL
``	NULL
seru	NULL
11	NULL
rru	NULL
``	NULL
EV	NULL
*	NULL
aru	NULL
YP4	NULL
aru	NULL
AY	NULL
uxser	NULL
3	NULL
'	NULL
LTRpuys	NULL
.	NULL

;	NULL
.	NULL

Introduction	NULL
of	NULL
a	NULL
frameshift	NULL
at	NULL
an	NULL
Neo	NULL
!	NULL

site	NULL
(	NULL
nucleotide	NULL
position	NULL
5255	NULL
)	NULL
in	NULL
HXBRU*	NULL
generated	NULL
a	NULL
provirus	NULL
expressing	NULL
a	NULL
truncated	NULL
vpr	NULL
product	NULL
(	NULL
HXBRU~	NULL
)	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
location	NULL
of	NULL
the	NULL
recently	NULL
identified	NULL
coding	NULL
sequences	NULL
of	NULL
the	NULL
(	NULL
inv	NULL
)	NULL
fusion	NULL
protein	NULL
is	NULL
shown	NULL
(	NULL
7a	NULL
)	NULL
.	NULL

3098	NULL
NOTES	NULL
J.	NULL
Viror	NULL
.	NULL

A	NULL
B	NULL
1	NULL
2.	NULL
a	NULL
4	NULL
8.0.1	NULL
2	NULL
8.4	NULL
c	NULL
100	NULL
60	NULL
[	NULL
-|	NULL
90	NULL
=	NULL
gp	NULL
160/120	NULL
50	NULL
|-	NULL
-|	NULL
80	NULL
-|	NULL
70	NULL
40	NULL
[	NULL
-	NULL
-|	NULL
eo	NULL
-|	NULL
50	NULL
30	NULL
|	NULL
--	NULL
|	NULL
40	NULL
Sucrose	NULL
(	NULL
%	NULL
)	NULL
20	NULL
|-	NULL
-|	NULL
30	NULL
-|	NULL
20	NULL
Reverse	NULL
Transcriptase	NULL
Activity	NULL
(	NULL
10	NULL
8	NULL
counts/min	NULL
)	NULL
[	NULL
35	NULL
S	NULL
]	NULL
Cysteine-Labeled	NULL
Proteins	NULL
(	NULL
103	NULL
counts/min	NULL
)	NULL
1	NULL
8	NULL
Fractions	NULL
18kd	NULL
15k	NULL
-	NULL
Sucrose	NULL
Gradient	NULL
Fractions	NULL
103kd	NULL
-	NULL
``	NULL
4-	NULL
gp120	NULL
67kd	NULL
-	NULL
sti	NULL
.	NULL

coas	NULL
wills	NULL
41kd	NULL
«	NULL
lls	NULL
28kd	NULL
-	NULL
@	NULL
&	NULL
D	NULL
T	NULL
am	NULL
an	NULL
o-	NULL
=	NULL
4-	NULL
p24	NULL
18kd	NULL
-	NULL
,	NULL
«	NULL
-	NULL
C	NULL
a	NULL
»	NULL
-	NULL
4-	NULL
p17	NULL
15kd	NULL
-	NULL
«	NULL
wee	NULL
w	NULL
<	NULL
-	NULL
vor	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Detection	NULL
of	NULL
the	NULL
vpr	NULL
product	NULL
in	NULL
the	NULL
extracellular	NULL
virions	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Lysates	NULL
prepared	NULL
from	NULL
[	NULL
*SJcysteine-labeled	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
HXBRU	NULL
*	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
or	NULL
HXBRU~	NULL
(	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
provirus	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
vpr	NULL
peptide	NULL
antiserum	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
,	NULL
vpr	NULL
peptide	NULL
antiserum	NULL
preincubated	NULL
with	NULL
500	NULL
wmol	NULL
of	NULL
peptide	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
,	NULL
or	NULL
AIDS	NULL
patient	NULL
serum	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Lysates	NULL
of	NULL
pelleted	NULL
virus	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
HXBRU*	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
HXBRU~	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
provirus	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
vpr	NULL
peptide	NULL
antiserum	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
AIDS	NULL
patient	NULL
serum	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Pelieted	NULL
virions	NULL
prepared	NULL
from	NULL
[	NULL
*S	NULL
]	NULL
cysteine-labeled	NULL
HXBRU	NULL
*-transfected	NULL
Jurkat	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
400	NULL
pl	NULL
of	NULL
TNE	NULL
,	NULL
layered	NULL
on	NULL
a	NULL
15	NULL
to	NULL
60	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
sucrose	NULL
gradient	NULL
,	NULL
and	NULL
centrifuged	NULL
at	NULL
45,000	NULL
rpm	NULL
for	NULL
3	NULL
h	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Eleven	NULL
fractions	NULL
(	NULL
400	NULL
pl	NULL
each	NULL
)	NULL
were	NULL
collected	NULL
.	NULL

Reverse	NULL
transcriptase	NULL
assays	NULL
(	NULL
7	NULL
)	NULL
were	NULL
performed	NULL
on	NULL
50-pl	NULL
portions	NULL
of	NULL
each	NULL
fraction	NULL
(	NULL
&	NULL
)	NULL
.	NULL

Ten	NULL
microliters	NULL
of	NULL
each	NULL
fraction	NULL
was	NULL
counted	NULL
in	NULL
a	NULL
liquid	NULL
scintillation	NULL
counter	NULL
to	NULL
determine	NULL
the	NULL
amount	NULL
of	NULL
[	NULL
**S	NULL
]	NULL
cysteine-labeled	NULL
proteins	NULL
(	NULL
@	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Immunoprecipitates	NULL
of	NULL
either	NULL
240	NULL
or	NULL
100	NULL
pl	NULL
of	NULL
each	NULL
sucrose	NULL
gradient	NULL
fraction	NULL
with	NULL
vpr	NULL
peptide	NULL
antiserum	NULL
(	NULL
a	NULL
)	NULL
or	NULL
AIDS	NULL
patient	NULL
antiserum	NULL
(	NULL
b	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

kd	NULL
,	NULL
Kilodaltons	NULL
.	NULL

Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
be	NULL
specific	NULL
,	NULL
since	NULL
in	NULL
similar	NULL
experiments	NULL
using	NULL
this	NULL
and	NULL
other	NULL
proviruses	NULL
,	NULL
monospecific	NULL
antiserum	NULL
to	NULL
the	NULL
fat	NULL
,	NULL
rev	NULL
,	NULL
vpu	NULL
,	NULL
and	NULL
nef	NULL
proteins	NULL
did	NULL
not	NULL
detect	NULL
these	NULL
proteins	NULL
in	NULL
the	NULL
pelleted	NULL
fraction	NULL
of	NULL
the	NULL
viruses	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
rule	NULL
out	NULL
cell	NULL
contamination	NULL
in	NULL
the	NULL
supernatant	NULL
,	NULL
the	NULL
suspended	NULL
HXBRU	NULL
*	NULL
virus	NULL
pellet	NULL
was	NULL
layered	NULL
onto	NULL
a	NULL
sucrose	NULL
gradient	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
virus	NULL
was	NULL
suspended	NULL
in	NULL
400	NULL
pl	NULL
of	NULL
a	NULL
buffer	NULL
(	NULL
TNE	NULL
)	NULL
which	NULL
contained	NULL
Tris	NULL
(	NULL
10	NULL
mM	NULL
;	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
.	NULL

A	NULL
4-mi	NULL
linear	NULL
sucrose	NULL
gradient	NULL
(	NULL
15	NULL
to	NULL
60	NULL
%	NULL
,	NULL
wt/vol	NULL
)	NULL
spun	NULL
at	NULL
45,000	NULL
rpm	NULL
for	NULL
3	NULL
h	NULL
was	NULL
used	NULL
.	NULL

Eleven	NULL
fractions	NULL
of	NULL
400	NULL
ul	NULL
each	NULL
were	NULL
collected	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
[	NULL
°°S	NULL
)	NULL
Jcysteine-labeled	NULL
protein	NULL
in	NULL
each	NULL
fraction	NULL
and	NULL
the	NULL
reverse	NULL
transcriptase	NULL
activity	NULL
were	NULL
determined	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
each	NULL
fraction	NULL
was	NULL
precipitated	NULL
with	NULL
either	NULL
an	NULL
AIDS	NULL
patient	NULL
antiserum	NULL
or	NULL
the	NULL
monospecific	NULL
vpr	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
.	NULL

The	NULL
vpr	NULL
protein	NULL
cosedimented	NULL
with	NULL
virus	NULL
particles	NULL
by	NULL
all	NULL
measures	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

The	NULL
peak	NULL
of	NULL
vpr	NULL
protein	NULL
corresponds	NULL
to	NULL
the	NULL
peak	NULL
of	NULL
reverse	NULL
transcriptase	NULL
activity	NULL
,	NULL
the	NULL
peak	NULL
of	NULL
[	NULL
**SJcysteine-labeled	NULL
proteins	NULL
in	NULL
the	NULL
gradient	NULL
,	NULL
and	NULL
the	NULL
peak	NULL
of	NULL
virion	NULL
proteins	NULL
as	NULL
detected	NULL
by	NULL
AIDS	NULL
patient	NULL
antiserum	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
radioactivity	NULL
in	NULL
the	NULL
bands	NULL
corresponding	NULL
to	NULL
p24	NULL
,	NULL
p17	NULL
,	NULL
and	NULL
vpr	NULL
p15	NULL
protein	NULL
in	NULL
the	NULL
immunoprecipitates	NULL
of	NULL
cell	NULL
lysates	NULL
and	NULL
virus	NULL
particles	NULL
was	NULL
determined	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
the	NULL
ratios	NULL
of	NULL
the	NULL
proteins	NULL
associated	NULL
with	NULL
the	NULL
viral	NULL
particles	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
roughly	NULL
equivalent	NULL
,	NULL
between	NULL
5:1	NULL
and	NULL
10:1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
difficult	NULL
to	NULL
calculate	NULL
stoichiometry	NULL
from	NULL
such	NULL
measurements	NULL
because	NULL
the	NULL
efficiency	NULL
of	NULL
immunoprecipitation	NULL
may	NULL
vary	NULL
for	NULL
each	NULL
protein	NULL
,	NULL
the	NULL
results	NULL
indicate	NULL
that	NULL
multiple	NULL
vpr	NULL
proteins	NULL
were	NULL
incorporated	NULL
into	NULL
each	NULL
virion	NULL
.	NULL

The	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
demonstrate	NULL
that	NULL
the	NULL
vpr	NULL
protein	NULL
is	NULL
incorporated	NULL
into	NULL
cell-free	NULL
virus	NULL
particles	NULL
.	NULL

The	NULL
vpr	NULL
protein	NULL
is	NULL
the	NULL
first	NULL
regulatory	NULL
product	NULL
of	NULL
HIV-1	NULL
to	NULL
be	NULL
found	NULL
associated	NULL
with	NULL
viral	NULL
particles	NULL
.	NULL

Experiments	NULL
similar	NULL
to	NULL
these	NULL
failed	NULL
to	NULL
detect	NULL
the	NULL
fat	NULL
,	NULL
rev	NULL
,	NULL
vpu	NULL
,	NULL
or	NULL
nef	NULL
protein	NULL
associated	NULL
with	NULL
virus	NULL
particles	NULL
(	NULL
E.	NULL
A.	NULL
Cohen	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

The	NULL
vpx	NULL
protein	NULL
of	NULL
HIV	NULL
type	NULL
2	NULL
and	NULL
of	NULL
the	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
was	NULL
also	NULL
recently	NULL
reported	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
the	NULL
virus	NULL
particles	NULL
(	NULL
12	NULL
)	NULL
.	NULL

There	NULL
is	NULL
no	NULL
similarity	NULL
in	NULL
amino	NULL
acid	NULL
sequence	NULL
between	NULL
the	NULL
vpr	NULL
and	NULL
vpx	NULL
proteins	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
vpr	NULL
becomes	NULL
associated	NULL
with	NULL
the	NULL
virus	NULL
particle	NULL
is	NULL
unknown	NULL
.	NULL

Other	NULL
capsid	NULL
proteins	NULL
are	NULL
made	NULL
as	NULL
gag	NULL
or	NULL
gag-pol	NULL
precursors	NULL
and	NULL
assembled	NULL
as	NULL
units	NULL
into	NULL
the	NULL
budding	NULL
particle	NULL
(	NULL
4	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
vpr	NULL
protein	NULL
is	NULL
not	NULL
known	NULL
to	NULL
be	NULL
part	NULL
of	NULL
such	NULL
a	NULL
larger	NULL
precursor	NULL
and	NULL
must	NULL
have	NULL
an	NULL
independent	NULL
means	NULL
of	NULL
association	NULL
with	NULL
the	NULL
nascent	NULL
particle	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
transactivating	NULL
protein	NULL
in	NULL
the	NULL
mature	NULL
virus	NULL
particles	NULL
suggests	NULL
that	NULL
this	NULL
protein	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
early	NULL
steps	NULL
of	NULL
virus	NULL
infection	NULL
.	NULL

Possible	NULL
roles	NULL
for	NULL
such	NULL
a	NULL
protein	NULL
include	NULL
facilitation	NULL
of	NULL
the	NULL
reverse	NULL
transcription	NULL
reaction	NULL
,	NULL
stabilization	NULL
of	NULL
RNA	NULL
,	NULL
stabilization	NULL
of	NULL
RNA-DNA	NULL
or	NULL
DNA-DNA	NULL
structures	NULL
,	NULL
facilitated	NULL
migration	NULL
of	NULL
the	NULL
proviral	NULL
DNA	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
and	NULL
facilitated	NULL
integration	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
vpr	NULL
protein	NULL
to	NULL
increase	NULL
the	NULL
rate	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
HIV-1	NULL
and	NULL
other	NULL
promoters	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
virion-associated	NULL
vpr	NULL
may	NULL
activate	NULL
early	NULL
transcription	NULL
of	NULL
the	NULL
HIV-1	NULL
NOTES	NULL
3099	NULL
provirus	NULL
.	NULL

The	NULL
vpr	NULL
product	NULL
may	NULL
also	NULL
alter	NULL
cellular	NULL
expression	NULL
before	NULL
viral	NULL
RNA	NULL
transcription	NULL
begins	NULL
.	NULL

Alteration	NULL
of	NULL
the	NULL
cell	NULL
environment	NULL
by	NULL
vpr	NULL
carried	NULL
into	NULL
the	NULL
cell	NULL
by	NULL
the	NULL
infecting	NULL
virus	NULL
may	NULL
alter	NULL
the	NULL
initial	NULL
rate	NULL
of	NULL
HIV-1	NULL
RNA	NULL
accumulation	NULL
before	NULL
viral	NULL
proteins	NULL
are	NULL
made	NULL
de	NULL
novo	NULL
.	NULL

We	NULL
thank	NULL
Udy	NULL
Olshevsky	NULL
for	NULL
helpful	NULL
discussions	NULL
,	NULL
A.	NULL
Emmert	NULL
for	NULL
artwork	NULL
,	NULL
and	NULL
J.	NULL
Welch	NULL
for	NULL
manuscript	NULL
preparation	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
Al28785	NULL
,	NULL
CA44460	NULL
,	NULL
and	NULL
AlI24845	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
to	NULL
W.A.H	NULL
.	NULL

E.A.C	NULL
.	NULL

is	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
Schering-Plough	NULL
fellowship	NULL
.	NULL

J.G.S	NULL
.	NULL

is	NULL
a	NULL
scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Barre-Sinoussi	NULL
,	NULL
F.	NULL
,	NULL
J.-C.	NULL
Chermann	NULL
,	NULL
F.	NULL
Rey	NULL
,	NULL
M.	NULL
T.	NULL
Nugeyre	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
J.	NULL
Gruest	NULL
,	NULL
C.	NULL
Dauguet	NULL
,	NULL
C.	NULL
Axler-Blin	NULL
,	NULL
F.	NULL
Brun-Vezinet	NULL
,	NULL
C.	NULL
Rouzioux	NULL
,	NULL
W.	NULL
Rozenbaum	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1983	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
T-lymphotropic	NULL
retrovirus	NULL
from	NULL
a	NULL
patient	NULL
at	NULL
risk	NULL
for	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
.	NULL

Science	NULL
220:868-871	NULL
.	NULL

2	NULL
.	NULL

Cohen	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
E.	NULL
F.	NULL
Terwilliger	NULL
,	NULL
Y.	NULL
Jalinoos	NULL
,	NULL
J.	NULL
Proulx	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
HIV-1	NULL
vpr	NULL
product	NULL
and	NULL
function	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

3	NULL
:	NULL
11-18	NULL
.	NULL

3	NULL
.	NULL

Haseltine	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

1988	NULL
.	NULL

Replication	NULL
and	NULL
pathology	NULL
of	NULL
the	NULL
AIDS	NULL
virus	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

1:217-240	NULL
.	NULL

4	NULL
.	NULL

Jacks	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
D.	NULL
Power	NULL
,	NULL
F.	NULL
R.	NULL
Masiarz	NULL
,	NULL
P.	NULL
Z.	NULL
Luciw	NULL
,	NULL
P.	NULL
J.	NULL
Barr	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Varmus	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
ribosomal	NULL
frame-shifting	NULL
in	NULL
HIV-1	NULL
gag-pol	NULL
expression	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
331	NULL
:	NULL
280-283	NULL
.	NULL

5	NULL
.	NULL

Ogawa	NULL
,	NULL
K.	NULL
,	NULL
R.	NULL
Shibata	NULL
,	NULL
T.	NULL
Kiyomasu	NULL
,	NULL
I.	NULL
Higuchi	NULL
,	NULL
Y.	NULL
Kishida	NULL
,	NULL
A.	NULL
Ishimoto	NULL
,	NULL
and	NULL
A.	NULL
Adachi	NULL
.	NULL

1989	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
vpr	NULL
open	NULL
reading	NULL
frame	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63	NULL
:	NULL
4110-4114	NULL
.	NULL

6	NULL
.	NULL

Ratner	NULL
,	NULL
L.	NULL
,	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
R.	NULL
Patarca	NULL
,	NULL
K.	NULL
J.	NULL
Livak	NULL
,	NULL
B.	NULL
Starcich	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
E.	NULL
Z.	NULL
Doran	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Rafalski	NULL
,	NULL
E.	NULL
A.	NULL
Whitehorn	NULL
,	NULL
K.	NULL
Baumeister	NULL
,	NULL
L.	NULL
Ivanoff	NULL
,	NULL
S.	NULL
R.	NULL
Petteway	NULL
,	NULL
M.	NULL
L.	NULL
Pearson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Lautenberger	NULL
,	NULL
T.	NULL
S.	NULL
Papas	NULL
,	NULL
J.	NULL
Ghrayeb	NULL
,	NULL
N.	NULL
Chang	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1985	NULL
.	NULL

Complete	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
AIDS	NULL
virus	NULL
,	NULL
HTLV-III	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
313:277-283	NULL
.	NULL

7	NULL
.	NULL

Rho	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
B.	NULL
Poiesz	NULL
,	NULL
F.	NULL
W.	NULL
Ruscetti	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1981	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
reverse	NULL
transcriptase	NULL
from	NULL
a	NULL
new	NULL
retrovirus	NULL
(	NULL
HTLV	NULL
)	NULL
produced	NULL
by	NULL
a	NULL
human	NULL
cutaneous	NULL
T-cell	NULL
lymphoma	NULL
cell	NULL
line	NULL
.	NULL

Virology	NULL
112:355-360	NULL
.	NULL

7a.Salfeld	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Gottlinger	NULL
,	NULL
R.	NULL
Sia	NULL
,	NULL
R.	NULL
Park	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
tripartite	NULL
HIV-1	NULL
ftat-env-rev	NULL
fusion	NULL
protein	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:965-970	NULL
.	NULL

8	NULL
.	NULL

Sodroski	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1984.	NULL
trans-Acting	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
human	NULL
T	NULL
lymphotropic	NULL
viruses	NULL
in	NULL
infected	NULL
cells	NULL
.	NULL

Science	NULL
225:381-385	NULL
.	NULL

9	NULL
.	NULL

Terwilliger	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
E.	NULL
A.	NULL
Cohen	NULL
,	NULL
Y.	NULL
Lu	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1989	NULL
.	NULL

Functional	NULL
role	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
vpu	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:5163-5167	NULL
.	NULL

10	NULL
.	NULL

Wain-Hobson	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Sonigo	NULL
,	NULL
O.	NULL
Danos	NULL
,	NULL
S.	NULL
Cole	NULL
,	NULL
and	NULL
M.	NULL
Alizon	NULL
.	NULL

1985	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
AIDS	NULL
virus	NULL
,	NULL
LAV	NULL
.	NULL

Cell	NULL
40:8-17	NULL
.	NULL

11	NULL
.	NULL

Weiss	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
N.	NULL
Teich	NULL
,	NULL
H.	NULL
Varmus	NULL
,	NULL
and	NULL
J.	NULL
Coffin	NULL
.	NULL

1984	NULL
.	NULL

Molecular	NULL
biology	NULL
of	NULL
tumor	NULL
viruses	NULL
:	NULL
RNA	NULL
tumor	NULL
viruses	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
12	NULL
.	NULL

Yu	NULL
,	NULL
X.-F.	NULL
,	NULL
S.	NULL
Ito	NULL
,	NULL
M.	NULL
Essex	NULL
,	NULL
and	NULL
T.	NULL
H.	NULL
Lee	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
naturally	NULL
immunogenic	NULL
virion-associated	NULL
protein	NULL
specific	NULL
for	NULL
HIV-2	NULL
and	NULL
SIV	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
335:262-265	NULL
.	NULL

